Results of the Cystic Fibrosis HealthHub Trial
In this webinar, Dr Martin Wildman explains why preventative therapy for Cystic Fibrosis patients is even more important than before, especially in the light of improvement in their lung health by taking cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Dr Wildman highlights the importance of sustained self-care in Cystic Fibrosis and provides an overview of the CF HealthHub program: how it helps Cystic Fibrosis patients to continue to take preventative therapy with the aim of helping build habits and develop adherence to treatments.
We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.
Dr Martin Wildman
Dr Wildman is a consultant in respiratory medicine and adult cystic fibrosis at Sheffield Teaching Hospital. He trained in Health Services Research at the London School of Hygiene and Tropical Medicine, and joined ScHARR as an honorary senior lecturer in health services research in 2013. Dr Wildman is also involved in quality improvement as part of CF HealthHub and have a role within the Sheffield Microsystems Coaching academy.